Monograph

A04AA02 - Granisetron

Propably not porphyrinogenic

Rationale

Substrate for CYPs 3A4 and 3A5. No data pointing to clinical CYP-induction. One reference: authorised.

Chemical description

Selective 5-HT-antagonist used as prophylaxis or treatment of postoperative nausea and nausea under chemotherapy ; 2-9 mg/d perorally or parenterally. Metabolized mainly by CYP 3A4. No instances of CYP-induction observed clinically. South African list: No data/avoid. French list: authorized

IPNet drug reports

Uneventful use reported in 2 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes A04A / A04AA or go back.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames